Welcome to our dedicated page for FOXO Technologies SEC filings (Ticker: FOXOW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The FOXO TECHNOLOGIES INC WTS (FOXOW) SEC filings page on Stock Titan provides access to regulatory documents filed by FOXO Technologies Inc. with the U.S. Securities and Exchange Commission. These filings are a primary source of information about the company’s capital structure, preferred stock designations, warrant issuances, acquisitions, and governance actions that can affect holders of warrants and other securities.
Recent Form 8-K filings describe amendments to the company’s Certificate of Incorporation and Amended and Restated Certificates of Designation for several series of preferred stock, including Series B, Series C, Series D, and Series E. These documents outline revised conversion prices, clarify dividend payment timing, and set out other rights, privileges, and preferences. The filings state that the summaries are qualified in their entirety by reference to the full certificates attached as exhibits.
Other 8-Ks report increases in authorized shares of Class A Common Stock and Preferred Stock, approved by a majority stockholder through written consent. These filings also discuss the re-election of directors and the non-binding ratification of the company’s independent registered public accounting firm, along with references to preliminary and definitive Information Statements on Schedule 14C that explain these actions to stockholders.
Filings further detail the completion of the acquisition of Vector Bio Source Inc., where the sellers received cash, shares of Series E Cumulative Redeemable Secured Preferred Stock, and warrants to purchase Class A Common Stock. A form of the warrant agreement is filed as an exhibit, providing the legal terms for those warrants. Another 8-K furnished under Regulation FD describes a press release recognizing the company’s behavioral health subsidiary, Myrtle Recovery Centers, at an awards event.
On Stock Titan, these SEC filings are updated from EDGAR and paired with AI-powered summaries designed to explain the key points of each document in plain language. Users can quickly see what each 8-K, 10-K, 10-Q, or other form covers, while still having direct access to the full text and exhibits for detailed review.
FOXO Technologies Inc. obtained written consent from its Board and a majority voting stockholder to amend its charter to permit a reverse stock split of its common stock at a ratio between 1-for-10 and 1-for-500. The Board may choose the exact ratio and timing, any time before July 31, 2026, by filing a certificate of amendment in Delaware.
The reverse split is intended to raise FOXO’s very low OTC trading price to help meet the $0.01 OTCQB quotation threshold, potentially broaden institutional interest, and reduce certain costs. Based on 67,167,410 common shares outstanding as of September 2, 2025, the split would leave between 6,716,741 and 134,334 shares outstanding, while authorized common shares remain 500,000,000, increasing authorized but unissued capacity. Fractional shares will be rounded up to the nearest whole share, and stockholders’ percentage ownership and voting rights are expected to remain proportionate.
FOXO Technologies Inc. reports that its majority stockholder, Rennova Health, Inc., which is controlled by the company’s CEO, approved certain corporate actions by written consent as of September 10, 2025. Rennova Health held approximately 56.71% of FOXO’s voting rights directly or through proxy on that record date, giving it the ability to approve these matters without a stockholder meeting.
The company plans to file a preliminary Information Statement on Schedule 14C and then mail a definitive Schedule 14C to stockholders of record as of the same date. The approved items will become effective 20 days after the mailing of the definitive Information Statement, with further details to be provided in that document.
FOXO Technologies Inc. entered into a Stock Purchase Agreement to acquire all shares of Vector BioSource Inc. through its wholly owned subsidiary. At closing, the Vector sellers will receive
FOXO Technologies Inc. reported that it has signed a stock purchase agreement to acquire Vector Biosource Inc., a provider of information, data and biospecimen sourcing services to the biotechnology, clinical research and pharmaceutical research industries. The company shared this update via a furnished press release under a Regulation FD disclosure, meaning it is treating the announcement as general information rather than as filed financial data. The filing also highlights that statements about the acquisition and future performance are considered forward-looking and subject to risks and uncertainties.